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The yeast Wickerhamomyces anomalus has been proposed for many biotechnological applications in the food 
industry. However, a number of opportunistic pathogenic strains have been reported as causative agents of no-
socomial fungemia. Recognition of potentially pathogenic isolates is an important challenge for the future com-
mercialization of this yeast. The isolation of W. anomalus from different matrices and, recently, from mosquitoes, 
requires further investigations into its circulation in humans. Here we present a qPCR protocol for the detection 
of W. anomalus in human blood samples and the results of a screening of 525 donors, including different classes 
of patients and healthy people.
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Wickerhamomyces anomalus (also designated 
as Pichia anomala, Hansenula anomala and 
Candida pelliculosa) is an ascomycete yeast well 
known for its antimicrobial properties, that 
have led to this microorganism being consid-
ered a biocontrol agent (Walker, 2011). Some 
examples of applications of W. anomalus are: 
in food/feed biopreservation (Olstorpe and Pas-
soth, 2011), as a probiotic additive (Zuo et al., 
2013) and as a volatile aroma enhancer in wine 
making (Swangkeaw et al., 2009). This yeast 
has been isolated from different habitats or ma-
trices like food and feed systems (Walker, 2011) 
and even from insects (Toki et al., 2012, Ricci 
et al., 2011a). The identification of antimicrobi-
al W. anomalus strains in Anopheles and Aedes 
mosquitoes have led this yeast being proposed 
also in the biocontrol of malaria (Cappelli et 
al., 2014, Ricci et al., 2011b) and other mosqui-
to-borne diseases (Ricci et al., 2011a).
With regard to food safety aspects, W. anomalus 
is classed at biosafety level 1 by the European 
Food Safety Authority (De Hoog, 1996). In ad-
dition, there are no reports in the literature on 
hazardous mycotoxin formation or allergic re-
actions to the spores from this yeast. However, a 
number W. anomalus strains have been isolated 
from humans, raising the possibility that this 
yeast is an emerging opportunistic pathogen 
(Hazen, 1995, Kalkanci et al., 2010). In particu-
lar, reports over the last decades have highlight-
ed an increase in nosocomial yeast bloodstream 
infections, particularly pediatric outbreaks, due 
to uncommon species, including W. anomalus 
(Taj-Aldeen et al., 2014). W. anomalus infections 
have been reported in cancer patients (Thuler 
et al., 1997), infants and premature neonates 
(Aragão et al., 2001, Oliveira et al., 2014), and in 
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patients in surgical intensive care units (Kalen-
ic et al., 2001). Possible explanations for the 
emergence of opportunistic pathogenic yeasts 
could be the increase in the number of patients 
at risk, such as immunocompromised persons, 
and the contribution of more sensitive diag-
nostic methods. However, the reasons for the 
increased incidence of fungemia from uncom-
mon pathogenic yeasts are not completely clear. 
Differentiating non-pathogenic strains from 
potential opportunistic pathogens is necessary 
for future biotechnological applications of W. 
anomalus (Passoth et al., 2011). In addition, the 
recent isolation of a W. anomalus strain from 
different mosquito species (Ricci et al., 2011a) 
has set a new alert, considering that hemato-
phagous insects might play a role in spreading 
this microorganism.
Here, we present a qPCR protocol for the detec-
tion of W. anomalus using species-specific prim-
ers previously designed (Huang et al., 2012), 
aimed at improving the current procedures for 
the rapid diagnosis of infections by this yeast. 
This optimized qPCR protocol was applied in 
a screening study to estimate the circulation 
of W. anomalus in human blood samples from 
different classes of patients (including immu-
nocompromised) and from healthy donors.
We carried out a retrospective analysis using 
previously collected blood samples. A total of 
525 donors were examined by qPCR (Table 1): 
243 blood samples, collected between January 
2011 and November 2012 from critically ill pa-
tients (adult and pediatric patients with suspi-
cion of sepsis) admitted to the Intensive Care 
Units and Haematology Units (ICUs & HU) at 
the St. Orsola Malpighi University Hospital of 
Bologna; 183 blood samples, collected at the S. 
Matteo Hospital of Pavia in the context of an-
other study, from 20 HIV, 61 HCV, and 19 HIV/
HCV positive patients, and 83 healthy donors; 
99 blood samples from additional 81 healthy 
donors collected at St. Orsola Malpighi, 10 ma-
laria patients collected at Spedali Civili di Bres-
cia (Institute for Infectious and Tropical Dis-
eases, IITD) and 8 workers at the insectary of 
the University of Camerino (Unicam). All of the 
samples included in the present study were ob-
tained and analysed in strict accordance with 
the current European and Italian rules on in-
formed consent.
The results of this screening for W. anomalus 
(Wa) in blood samples required the develop-
ment of a highly specific and sensitive qPCR 
assay. For the protocol optimization 12 yeast 
isolates (eight representing W. anomalus; four 
representing other yeast species) were used as 
control strains: WaF17.12, WaM9.11, Candida 
sp. and Pichia sp. isolated from the malaria vec-
tor mosquito An. stephensi (Ricci et al., 2011b); 
the environmental strains WaATCC 996603 and 
WaUM3 (Polonelli et al., 1997), Saccaromyces 
cerevisiae ATCC 2601 and Williopsis saturnus 
var. mrakii (Guyard et al., 2002); four clinical 
isolates of W. anomalus from four neonates 
hospitalized in an intensive care unit (Kalkanci 
et al., 2010). In the qPCR standard curve set-
up, a target sequence of 218 bp of b-tubulin 
TABLE 1 - Summary of the screening for Wickerhamomyces anomalus (Wa) in human blood samples.
Human samples and health  
or disease status
Samples origin Wa-qPCR assay results 
positive/total
Critically ill patients St. Orsola Malpighi/ICUs & HU, 
University Hospital of Bologna
0/243* (36 pediatric cases;  
207 adults cases)
HIV positive patients S. Matteo, Hospital of Pavia 0/20
HCV positive patients S. Matteo, Hospital of Pavia 1/61
HIV/HCV positive patients S. Matteo, Hospital of Pavia 0/19
Malaria patients Spedali Civili di Brescia/ IITD 0/10
Donors exposed to mosquito  
bites at insectary
Unicam 0/8
Healthy blood donors S. Matteo, Hospital of Pavia 0/83
Healthy blood donors St. Orsola Malpighi, University 
Hospital of Bologna
0/81
Total 1/525
*All of these patients displayed at least two signs among the criteria of the systemic inflammatory response syndrome (Kaukonen et al., 2015).
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gene was amplified using the specific primers 
SpWanom-170F (5’TTATCCATCCACCAATTG3’) 
and SpWanom-374R (5’GGAACTAAGTTCA-
CAGCTA3’) (Huang et al., 2012). The primers 
were previously tested against yeast genomic 
DNAs from all of 12 isolates listed above. The 
expected amplicon was obtained from all eight 
W. anomalus isolates tested (two isolated from 
mosquito, two environmental and four clinical 
isolates), while no amplification was obtained 
from the other four yeast isolates, representing 
other species (Candida sp., Pichia sp., Saccaro-
myces cerevisiae ATCC 2601 and Williopsis sat-
urnus var. mrakii).
To evaluate the amplification efficiency of 
the selected primers, the PCR product from 
WaF17.12 was cloned into a plasmid vector 
(pGEM-T Easy Vector System, Promega, Wis-
consin, USA) and the amount of the recombi-
nant plasmid was determined. We carried out 
a standard curve, using as DNA templates eight 
serial dilutions (10-1) of the recombinant plas-
mid, corresponding to around 2.3x107 – 2.3 gene 
copies per µl of reaction. qPCR amplifications 
were carried out with the b-tubulin gene prim-
ers (200 nM each) using Sybr Green Master Mix 
(Fermentas, Burlington, Canada) in a final vol-
ume of 25 µl. Amplification cycling conditions 
were as follows: 10’ at 95°C; 1’ at 95°C, 1’ at 
52°C, 30’’ at 72°C for 40 cycles. A final step for 
the melting curve analysis from 65°C to 95°C 
(increment of +0.5°C) was performed and the 
relative dissociation curve displayed a single 
specific dissociation peak at 74.50°C. The ob-
tained standard curve showed high sensitivity, 
up to around 2.3 gene copies per µl of PCR re-
action were detected.
The qPCR protocol was then validated mixing 
W. anomalus cells with human blood samples. 
We tested the strain WaF17.12 and the four 
clinical isolates of W. anomalus. The yeasts 
were grown in YPD medium and incubated 
overnight at 28°C at 110 rpm to obtain an op-
tical density 1.0 (3.2x107 cells/ml). Yeast cells 
were collected by centrifugation at 3500 rcf, 
4°C for 10’ and diluted in sterile water. Eight 
serial dilutions from 3.2 x107 cells to 3.2 cells 
were obtained in a final volume of 200 µl of hu-
man blood samples from a healthy donors (in 
triple replicates for each isolates). Total DNAs 
were extracted using the Jet Quick Blood DNA 
Spin Kit (Gentaur, Löhne, Germany) and sus-
pended in 50 µl of sterile water. Fifty ng of the 
purified DNAs were used as templates for qPCR 
analysis at the same conditions described for 
the standard curve set-up. The relative dissoci-
ation curves confirmed the same melting tem-
perature as the standard curve, while no spe-
cific peak was detected in the negative control 
reactions carried out with pure blood samples. 
The sequence analysis of the amplified product 
confirmed 100% homology with the GeneBank 
W. anomalus partial sequence of ß-tubulin gene 
available in GeneBank (JQ734945.1). The qPCR 
assay was able to detect up to around 16 yeast 
cells per ml of blood sample, for all the tested 
isolates (WaF17.12 and four W. anomalus clin-
ical isolates).
After the validation of the Wa-qPCR assay, we 
proceeded to screen the 525 selected blood 
samples. The DNA from these samples was 
obtained as described in Epis et al. (2012) and 
quantity and quality of the extracted samples 
were checked by spectrophotometer. Each 
sample was tested in triplicate (both undiluted 
and at a 1:10 dilution) and the positive control 
(DNA from WaF17.12 strain) was included. The 
template DNAs were subjected to the Wa-qPCR 
assay at the amplification conditions previously 
described. In addition, an amplification control 
was performed by running a parallel PCR test 
targeting the human Beta-2-microglobulin. Be-
ta-2-microglobulin amplification was carried 
out using a new primer set, Bmicr2F (5’CTC-
CGTGGCCTTAGCTGTG3’) and Bmicr2R 
(5’TTTGGAGTACGCTGGATAGCCT3’) (250 nM 
each) that amplifies a 69 bp fragment, follow-
ing the conditions described for W. anomalus 
detection except for the annealing step (60°C 
for 30’’).
The present study analysed a heterogeneous 
group, including healthy donors and different 
types of patients (critically ill adults and chil-
dren, HIV and HCV patients, malaria patients), 
blood donors exposed to mosquito bites and 
healthy donors, in order to have an overview 
of the yeast circulation in humans exposed at 
different types of risk. The screening revealed 
an almost complete negativity of the analysed 
samples, with the exception of a single HCV 
patient that tested positive (3.9 copies of ß-tu-
bulin gene per µl of reaction) at the Wa-qPCR 
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assay (Table 1). Sequence analysis of the am-
plified product revealed the perfect match of 
the amplified fragment with the b-tubulin gene 
from W. anomalus (JQ734945.1). This newly 
obtained sequence was deposited in EMBL-EBI 
under the accession number LN680997. In ad-
dition, to confirm the positivity of this sample 
and the negativity of 30 samples (a sub-sample, 
casually selected), we performed a nested-PCR 
targeted at 18S rRNA gene, for the specific W. 
anomalus detection following the protocol pub-
lished in Ricci et al., 2011b. Application of this 
further method to the positive sample and to 
30 samples that were negative at the first PCR 
confirmed our results.
Our results support the view of W. anomalus as 
an organism considered safe for healthy indi-
viduals and are coherent with the evidence of 
an uncommon opportunistic yeast (Taj-Aldeen 
et al., 2014). As stated in a recent review of the 
literature, W. anomalus infections have been re-
ported occasionally and the occurrence of a few 
hundred positive cases (single cases and out-
breaks) worldwide is estimated over a period 
longer than twenty years (Kalkanci et al., 2010).
We found a single case out of 353 immunocom-
promised patients (St. Orsola Malpighi, 243; 
Spedali Civili di Brescia, 10; S. Matteo Hospital, 
100) and 164 healthy donors screened. Interest-
ingly, no positivity was found in the malaria 
patients (exposed to malaria vector mosquito 
bites in Burkina Faso) and in the workers at 
the insectary (exposed to Anopheles and Aedes 
mosquitoes bite and to W. anomalus cultures). 
Nevertheless, the recognition of potentially 
pathogenic isolates is required for any future 
biotechnological applications of this yeast as a 
biocontrol agent. Our quantitative assay aimed 
at performing rapid mass screenings may effec-
tively contribute to further investigations nec-
essary for a better understanding of the epide-
miology of W. anomalus infections.
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